A 2026 gastrointestinal stromal tumor strategy report covering disease burden, KIT and PDGFRA biology, clinical competition, deal activity and portfolio positioning.

A 2026 anaplastic thyroid cancer strategy report covering disease burden, BRAF and RET biology, clinical competition, deal signals and portfolio positioning.

A 2026 differentiated thyroid cancer strategy report covering disease burden, RET and BRAF biology, clinical competition, deal signals and portfolio positioning.

A 2026 head and neck squamous cell carcinoma strategy report covering epidemiology, PD-1 and EGFR biology, clinical competition, deals and portfolio positioning.

A 2026 nasopharyngeal carcinoma strategy report covering epidemiology, PD-1 and EGFR biology, clinical competition, deal signals and portfolio positioning.

A 2026 mantle cell lymphoma strategy report covering disease burden, BTK and BCL-2 biology, clinical competition, deal activity and portfolio positioning.

Patrys 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Amplia Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Noxopharm 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Race Oncology 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Dimerix 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Starpharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.